Abstract
A multi-domain molecular model of factor IXa was constructed by comparative methods. The quaternary structure of the protein was assembled by docking individual domains through consideration of their shape complementarity, polaric properties and the location of cross-reacting material positive/negative (CRM+/−) variants on domain surfaces. Some 217 different missense mutations in the factor IX (F9) gene were then selected for study. Using maximum likelihood analysis, missense mutations affecting highly conserved amino acid residues of factor IX were shown to be 15–20 times more likely to result in haemophilia B than those affecting non-conserved residues. However, about one quarter of this increase in likelihood of clinical observation could be attributed to the magnitude of the amino acid exchange. Missense mutations in structurally conserved residues were found to be 2.1-fold more likely to come to clinical attention than those in structurally variable residues. Missense mutations in residues whose side chains were inwardly pointing were 3.6-fold more likely to be observed than those in surface residues. These observations imply a complex hierarchy of sequence/structure conservation in the protein. The severity of the clinical phenotype correlated with both the extent of the evolutionary sequence conservation of the residue at the site of mutation and the magnitude of the amino acid exchange. Further, the substitution of residues exhibiting minimal side chain solvent accessibility was associated disproportionately with severe haemophilia compared with that of surface residues. Clusters of CRM+ mutations were observed at factor IX-specific residues on the surface of the molecule. These clusters may reflect factor IX-specific docking interactions. The likelihood that a given factor IX mutation will come to clinical attention is therefore a complex function of the sequence characteristics of the F9 gene, the nature of the amino acid substitution, its precise location and immediate environment within the protein molecule, and its resulting effects on the structure and function of the protein.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alber T (1989) Mutational effects on protein stability. Annu Rev Biochem 58: 765–798
Armstrong SA, Husten EJ, Esmon CT, Johnson AE (1990) The active site of membrane-bound meizothrombin. A fluorescence determination of its distance from the phospholipid surface and its conformational sensitivity to calcium and factor Va. J Biol Chem 265: 6210–6218
Bernstein TF, Koetzle TF, Williams GJB, Meyer EF, Brice MD, Rodgers JR, Kennard O, Shimanouchi T, Tasumi M (1977) The protein data bank: a computer-based archival file for macromolecular structures. J Mol Biol 112: 535–542
Bottema CDK, Ketterling RP, Setsuko L, Yoon H-S, Phillips JA, Sommer SS (1991) Missense mutations and evolutionary conservation of amino acids: evidence that many of the amino acids in factor IX function as “spacer” elements. Am J Hum Genet 49: 820–838
Campbell ID, Bork P (1993) Epidermal growth factor-like modules. Curr Opin Struct Biol 3: 385–392
Cherfils J, Janin J (1993) Protein docking algorithms: simulating molecular recognition. Curr Opin Struct Biol 3: 265–269
Cheung W-F, Straight DL, Smith KJ, Lin S-W, Roberts HR, Stafford DW (1991) The role of the epidermal growth factor-1 and hydrophobic stack domains of human factor IX in binding to endothelial cells. J Biol Chem 266: 8797–8800
Cheung W-F, Hamaguchi N, Smith KJ, Stafford DW (1992) The binding of human factor IX to endothelial cells is mediated by residues 3–11. J Biol Chem 267: 20529–20531
Cooper DN, Krawczak M (1990) The mutational spectrum of single base-pair substitutions causing human genetic disease: patterns and predictions. Hum Genet 85: 55–74
Cooper DN, Krawczak M (1993) Human gene mutation. Bios Scientific, Oxford
Creighton TE (1993) Proteins; structure and molecular properties. Freeman, New York
Dempster AP, Laird NM, Rubin DB (1977) Maximum likelihood from incomplete data via the EM algorithm (with Discussion). J R Stat Soc B 39: 1–38
Frazier D, Smith KJ, Cheung W-F, Ware J, Lin S-W, Thompson AR, Reisner H, Bajaj SP, Stafford DW (1989) Mapping of monoclonal antibodies to human factor IX. Blood 74: 971–977
Furie B, Bing DH, Feldmann RJ, Robison DJ, Burnier JP, Furie BC (1982) Computer-generated models of blood coagulation factor Xa, factor IXa and thrombin based upon structural homology with other serine proteases. J Biol Chem 257: 3875–3882
Giannelli F, Green PM, High KA, Sommer S, Poon M-C, Ludwig M, Schwaab R, Reitsma PH, Goossens M, Yoshioka A, Brownlee GG (1993) Haemophilia B: database of point mutations and short additions and deletions, 4th edn 1993. Nucleic Acids Res Suppl 21: 3075–3087
Grantham R (1974) Amino acid difference formula to help explain protein evolution. Science 185: 862–864
Greer J (1990) Comparative modelling methods: application to the family of the mammalian serine proteases. Proteins: Struct Funct Genet 7: 317–334
Hampsey DM, Das G, Sherman F (1986) Amino acid replacements in yeast iso-1-cytochrome c. J Biol Chem 261: 3259–3271
Hertzberg MS, Ben-Tal O, Furie B, Furie BC (1992) Construction, expression and characterization of a chimera of factor IX and factor X. The role of the second epidermal growth factor domain and serine protease domain in factor Va binding. J Biol Chem 267: 14759–14766
Ketterling RP, Bottema CDK, Koeberl DD, Ii S, Sommer SS (1991) T296→M, a common mutation causing mild hemophilia B in the Amish and others: founder effect, variability in factor IX activity assays, and rapid carrier detection. Hum Genet 87: 333–337
Kohde D, Inagaki F (1992) Three-dimensional structure nuclear magnetic resonance structures of mouse epidermal growth factor in acidic and physiological pH conditions. Biochemistry 31: 11928–11939
Lesk AM, Chothia C (1980) How different amino acid sequences determine similar protein structures: the structure and evolutionary dynamics of the globins. J Mol Biol 136: 225–270
Lim WA, Faruggio DC, Sauer RT (1992) Structural and energetic consequences of disruptive mutations in a protein core. Biochemistry 31: 4324–4333
Lin S-W, Smith KJ, Welsch D, Stafford DW (1990) Expression and characterization of human factor IX and factor IX-factor X chimeras in mouse C127 cells. J Biol Chem 265: 144–150
McCord DM, Monroe DM, Smith KJ, Roberts HR (1990) Characterization of the functional defect in factor IX Alabama. J Biol Chem 265: 10250–10254
Montelione G, Wüthrich K, Burgess AW, Nice EC, Wagner G, Gibson KD, Sheraga HA (1992) Solution structure of murine epidermal growth factor determined by NMR spectroscopy and refined by energy minimization with restraints. Biochemistry 31: 236–249
Needleman SB, Wünsch CP (1970) A general method applicable to the search for similarities in the amino acid sequence of two proteins. J Mol Biol 48: 443–453
Nishimura H, Takeya H, Suehiro K, Okamura T, Murakawa M, Niho Y, Miyata T, Iwanaga S (1991) Characterization of factor IX Fukuoka with substitution of Asn92 by His in the second epidermal growth factor-like domain. Thromb Haemost 65: 712
Nishimura H, Takeya H, Miyata T, Suehiro K, Okamura T, Niho Y, Iwanaga S (1993) Factor IX Fukuoka. Substitution of Asn92 by His in the second epidermal growth factor-like domain reults in defective interaction with factors VIIIa/X. J Biol Chem 268: 24041–24046
Padmanabhan K, Padmanabhan KP, Tulinsky A, Park CH, Bode W, Huber R, Blankenship DT, Cardin AD, Kisiel W (1993) Structure of human des(1–45) factor Xa at 2.2 Å resolution. J Mol Biol 232: 947–966
Pakula AA, Sauer RT (1989) Genetic analysis of protein stability and function. Annu Rev Genet 23: 289–310
Reiner AP, Davie EW (1994) The physiology and biochemistry of factor IX. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD (eds) Haemostasis and thrombosis, 3rd edn. Churchill Livingstone, Edinburgh
Roberts HR (1993) Molecular biology of hemophilia B. Thromb Haemost 70: 1–9
Sarkar G, Koeberl DD, Sommer SS (1990) Direct sequencing of the activation peptide and the catalytic domain of the factor IX gene in six species. Genomics 6: 133–143
Selander M, Persson E, Stenflo J, Drakenberg T (1990) 1H NMR assignment and secondary structure of the Ca2+-free form of the amino-terminal epidermal growth factor-like domain in coagulation factor X. Biochemistry 29: 8111–8118
Sommer SS, Bowie EJW, Ketterling RP, Bottema CDK (1992) Missense mutations and the magnitude of functional deficit: the example of factor IX. Hum Genet 89: 295–297
Soriano-Garcia M, Park CH, Tulinsky A, Ravichandran KG, Skrzypczak-Jankun E (1989) Structure of Ca2+ prothrombin fragment 1 including the conformation of the Gla domain. Biochemistry 28: 6805–6810
Stenflo J (1991) Structure-function relationships of epidermal growth factor modules in vitamin K-dependent clotting factors. Blood 78: 1637–1651
Swindells MB, Thornton JM (1991) Modelling by homology. Curr Opin Struct Biol 1: 219–223
Tulinsky A, Qiu X (1993) Active site and exosite binding of α-thrombin. Blood Coagul Fibrinolysis 4: 305–312
Vermeer C (1990) γ-Carboxyglutamate-containing proteins and the vitamin K-dependent carboxylase. Biochem J 266: 625–636
Vysotchin A, Medved LV, Ingham KC (1993) Domain structure and domain-domain interactions in human coagulation factor IX. J Biol Chem 268: 8436–8446
Wacey A, Pemberton S, Cooper DN, Kakkar VV, Tuddenham EGD (1993) A molecular model of the serine protease domain of activated protein C: application to the study of missense mutations causing protein C deficiency. Br J Haematol 84: 290–300
Wada K, Wada Y, Doi H, Ishibashi F, Gojibori T, Ikemura T (1991) Codon usage tabulated from the GenBank genetic sequence data. Nucleic Acids Res Suppl 19: 1981–1986
Yoshitake S, Schach BG, Foster DC, Davie EW, Kurachi K (1985) Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochemistry 24: 3736–3750
Author information
Authors and Affiliations
Additional information
This paper is dedicated to the memory of Andrew Wacey
Rights and permissions
About this article
Cite this article
Wacey, A.I., Krawczak, M., Kakkar, V.V. et al. Determinants of the factor IX mutational spectrum in haemophilia B: an analysis of missense mutations using a multi-domain molecular model of the activated protein. Hum Genet 94, 594–608 (1994). https://doi.org/10.1007/BF00206951
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00206951